Published in NMR Biomed on December 01, 2006
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol (2009) 2.33
Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging (2010) 1.82
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50
Biomedical applications of sodium MRI in vivo. J Magn Reson Imaging (2013) 1.02
Sodium MRI: methods and applications. Prog Nucl Magn Reson Spectrosc (2014) 0.93
Evaluation of treatment-associated inflammatory response on diffusion-weighted magnetic resonance imaging and 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography imaging biomarkers. Clin Cancer Res (2010) 0.90
Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem (2009) 0.88
In vivo magnetic resonance imaging of sodium and diffusion in rat glioma at 21.1 T. Magn Reson Med (2011) 0.84
Measurement techniques for magnetic resonance imaging of fast relaxing nuclei. MAGMA (2013) 0.80
Pharmacotherapy for adults with tumors of the central nervous system. Pharmacol Ther (2008) 0.78
Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience. Neuroimaging Clin N Am (2017) 0.75
²³Na-MRI of recurrent glioblastoma multiforme after intraoperative radiotherapy: technical note. Neuroradiology (2014) 0.75
New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst (1990) 23.46
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst (2000) 5.14
Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A (2005) 4.63
Image formation by induced local interactions. Examples employing nuclear magnetic resonance. 1973. Clin Orthop Relat Res (1989) 4.59
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15
Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res (1997) 2.96
MRI of the tumor microenvironment. J Magn Reson Imaging (2002) 2.87
Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther (2003) 2.28
Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer (1996) 2.20
Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. Radiology (2003) 1.77
Fast three dimensional sodium imaging. Magn Reson Med (1997) 1.76
Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging (2002) 1.53
Development of an animal brain tumor model and its response to therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res (1973) 1.51
Magnetic Resonance Imaging and Spectroscopy: Application to Experimental Neuro-Oncology. Q Magn Reson Biol Med (1) 1.43
Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther (2000) 1.42
Diffusion imaging for evaluation of tumor therapies in preclinical animal models. MAGMA (2004) 1.33
A comprehensive approach to the analysis and interpretation of the resonances of spins 3/2 from living systems. NMR Biomed (1991) 1.31
Brain tumor. Part 2. N Engl J Med (1991) 1.27
Brain-tumour drug resistance: the bare essentials. Lancet Oncol (2002) 1.21
Quantitative tissue sodium concentration mapping of normal rat brain. Magn Reson Med (1996) 1.20
Quantitative tissue sodium concentration mapping of the growth of focal cerebral tumors with sodium magnetic resonance imaging. Magn Reson Med (1999) 1.18
Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging. Clin Cancer Res (2000) 1.18
MR imaging of sodium in the human brain with a fast three-dimensional gradient-recalled-echo sequence at 4 T. Acad Radiol (2003) 1.03
Sodium magnetic resonance imaging of chemotherapeutic response in a rat glioma. Magn Reson Med (2005) 1.01
Magnetic resonance imaging in cancer research. Eur J Cancer (2002) 1.00
Sodium and proton diffusion MRI as biomarkers for early therapeutic response in subcutaneous tumors. Magn Reson Imaging (2006) 0.99
Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications. Technol Cancer Res Treat (2004) 0.92
Sodium 3-D MRI of the human torso using a volume coil. Magn Reson Imaging (2004) 0.88
Application of 23Na MRI to monitor chemotherapeutic response in RIF-1 tumors. Neoplasia (2005) 0.87
Clinical NMR spectroscopy of tumors. Current status and future directions. Invest Radiol (1989) 0.85
Fast three-dimensional sodium imaging of human brain. MAGMA (2001) 0.84
Sodium T2*-weighted MR imaging of acute focal cerebral ischemia in rabbits. Magn Reson Imaging (2004) 0.84
Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma. J Neurosurg (2004) 0.83
Genomics-based hypothesis generation: a novel approach to unravelling drug resistance in brain tumours? Lancet Oncol (2004) 0.82
Altered nuclear localization of bax protein in BCNU-resistant glioma cells. J Neurooncol (2000) 0.82
Characteristics of extracellular sodium relaxation in perfused hearts with pathologic interventions. Magn Reson Med (1992) 0.77
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia (2011) 5.53
Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A (2005) 4.63
Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: a multicenter prospective study (PIOPED III). Ann Intern Med (2010) 4.15
CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A (2007) 3.85
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15
Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials (2007) 3.12
Computed tomography-based biomarker provides unique signature for diagnosis of COPD phenotypes and disease progression. Nat Med (2012) 2.95
Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol (2010) 2.90
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
Meta-analysis of functional neuroimaging studies of emotion perception and experience in schizophrenia. Biol Psychiatry (2011) 2.76
Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience. Radiology (2005) 2.69
It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging (2002) 2.58
Towards hyperpolarized (13)C-succinate imaging of brain cancer. J Magn Reson (2007) 2.57
Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology (2012) 2.53
Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res (2006) 2.46
Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol (2007) 2.39
The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med (2009) 2.32
The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia (2006) 2.30
Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther (2003) 2.28
PASADENA hyperpolarization of succinic acid for MRI and NMR spectroscopy. J Am Chem Soc (2008) 2.27
Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography. J Nucl Med (2008) 2.22
A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol (2009) 2.10
Evaluation of lung MDCT nodule annotation across radiologists and methods. Acad Radiol (2006) 2.00
Affinity peptide for targeted detection of dysplasia in Barrett's esophagus. Gastroenterology (2010) 1.93
Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A (2002) 1.93
Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging (2010) 1.82
Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys (2005) 1.79
In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther (2003) 1.77
Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci (2003) 1.72
Molecular imaging of Akt kinase activity. Nat Med (2007) 1.68
Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev (2006) 1.66
A methodology for registration of a histological slide and in vivo MRI volume based on optimizing mutual information. Mol Imaging (2006) 1.63
T2-weighted MR imaging in the assessment of cirrhotic liver. Radiology (2004) 1.61
Multi-system repeatability and reproducibility of apparent diffusion coefficient measurement using an ice-water phantom. J Magn Reson Imaging (2012) 1.57
PASADENA hyperpolarization of 13C biomolecules: equipment design and installation. MAGMA (2008) 1.56
Hyperpolarized water as an MR imaging contrast agent: feasibility of in vivo imaging in a rat model. Radiology (2012) 1.54
Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol (2005) 1.54
Clinical proton MR spectroscopy in central nervous system disorders. Radiology (2014) 1.53
Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging (2002) 1.53
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50
Diffusion coefficient measurement using a temperature-controlled fluid for quality control in multicenter studies. J Magn Reson Imaging (2011) 1.50
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. Clin Cancer Res (2007) 1.48
Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A (2005) 1.44
AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A (2009) 1.43
Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res (2004) 1.42
Quality assurance of PASADENA hyperpolarization for 13C biomolecules. MAGMA (2008) 1.41